Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025
Pursuant to the article L. 233-8 II of the French 'Code de Commerce' and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or ' AMF ') General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (' Innate ' or the ' Company ') releases its total number of shares outstanding as well as its voting rights as of July 3, 2025:
(1) The total number of theoretical voting rights (or 'gross' voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. No voting rights attached to AGAP 2017.
(2) The total number of exercisable voting rights (or 'net' voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® (A ntibody-based NK cell E ngager T herapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).
Innate's portfolio includes several ANKET ® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.
Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.
Information about Innate Pharma shares
Disclaimer on forward-looking information and risk factors
This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including 'anticipate,' 'believe,' 'can,' 'could,' 'estimate,' 'expect,' 'may,' 'might,' 'potential,' 'intend,' 'should,' 'will,' or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ('AMF'), which is available on the AMF website http://www.amf-france.org or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ('SEC'), including the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.
In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Raymond James Starts Coverage of Republic Bancorp (RBCAA) Stock with a Market Perform
Republic Bancorp, Inc. (NASDAQ:RBCAA) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 27, Raymond James began coverage of the company's stock with a 'Market Perform' rating and no price target, as reported by The Fly. As per the firm, the company is positioned for incremental growth over the upcoming years despite near-term EPS growth headwinds from lower income from the Tax Refund Solutions segment and modest NIM pressure. The analyst opines that the bank has been strategic in making itself a commercially focused community bank, catering to business and retail customers. A customer walking into a bank branch, expressing the convenience of consumer banking services. The firm also noted Republic Bancorp, Inc. (NASDAQ:RBCAA)'s consistent growth, superior capital levels, and improved profitability. Overall, the firm opines that the risk/reward profile for Republic Bancorp, Inc. (NASDAQ:RBCAA)'s stock remains balanced. The company's Tax Refund Solutions segment saw net income of $19.6 million during Q1 2025 as compared to net income of $8.8 million in Q1 2024. The rise was mainly aided by a positive $10.3 million decrease in the estimated Provision for RAs and Early Season RAs versus Q1 2024, and a 30% rise in the average per-unit profitability for Refund Transfers. While we acknowledge the potential of RBCAA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RBCAA and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds' investor letters by entering your email address below. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
Regeneron Pharmaceuticals (REGN) and Sanofi Announce Approval of Dupixent® By US FDA
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi announced that the US FDA approved Dupixent® (dupilumab) for the treatment of adult patients with bullous pemphigoid (BP). The approval for bullous pemphigoid brings a novel treatment approach to patients and their caregivers. Also, this approval extends the ability of Dupixent to transform treatment paradigms for people who live with a variety of diseases with underlying type 2 inflammation, from common conditions such as asthma and atopic dermatitis, to rarer ones, including eosinophilic esophagitis and prurigo nodularis, and now including bullous pemphigoid. A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality. Dupixent demonstrated the potential to improve the most challenging effects of bullous pemphigoid, while, at the same time, supporting some patients in achieving sustained disease remission as well as decreased oral corticosteroid use. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) highlighted that the approval also reinforced the demonstrated safety profile of Dupixent in a broad age range of patients, from infants to elderly people, and throughout dermatological, respiratory, and gastrointestinal diseases. The FDA approval was on the basis of data from the pivotal ADEPT Phase 2/3 trial, which evaluated the efficacy and safety of Dupixent as compared to placebo in adults with moderate-to-severe BP. While we acknowledge the potential of REGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than REGN and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds' investor letters by entering your email address below. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Despite all the drama, trade uncertainty hasn't really hurt economic growth, Goldman Sachs says
President Donald Trump's policies may have disrupted trade, but not global economic activity. Investment, employment, and spending remain strong despite initial fears of a slowdown, wrote Goldman Sachs. Growth forecasts for this year have actually improved from earlier, more pessimistic calls. President Donald Trump's new policies may be upending the global trade order, but so far, they're not hitting the economy hard, wrote Goldman Sachs analysts. "There are very few signs that uncertainty is taking a toll on activity," analysts at Goldman Sachs wrote in a Thursday note. Even though the analysts had expected Trump's second term to slow economic activity, the numbers tell a different story. Since late 2024, investment, factory hiring, consumer spending, and broader economic activity have all stayed resilient across major developed and emerging markets. In fact, growth forecasts for both the second quarter and this full year have actually improved from earlier, more pessimistic calls. The analysts pointed out that in most economies, trade-exposed investment accounts for a small share of GDP, so the impact may just be "too small to see." New factory investment, especially in emerging markets, has dipped, but this accounts for just 0.2 to 0.3 percentage points of GDP in major economies. The analysts also wrote that uncertainty usually bites hardest when financial conditions tighten. But global liquidity has actually improved since the start of the year, making it easier for businesses to borrow money and invest. Meanwhile, activity and investment expectations that dipped in April — which coincided with Trump's "Liberation Day" announcement — have already bounced back on improved tariff news. "As such, while we continue to expect that tariffs will slow activity later this year, we expect this will be mostly driven by the direct impacts of tariffs rather than uncertainty around trade policy," they added. Goldman's report came as the US posted better-than-expected employment data in June. The economy added 147,000 jobs, and unemployment fell from 4.2% to 4.1%. Investor sentiment is upbeat, with the S&P 500 and the Nasdaq at record highs. To be sure, trade policy uncertainty remains high by historical standards, with Goldman's uncertainty index spiking after Trump's election. But that uncertainty has eased in recent months as Trump negotiates new trade deals. Some businesses did rush to ship goods to the US ahead of potential tariffs, a phenomenon known as "front-loading," which may have helped mask some issues. But even after controlling for that, Goldman analysts found little evidence of an "uncertainty drag" on growth. There were also few differences between economic activities in countries that did and didn't boost exports to the US this spring. "The uncertainty drag, therefore, appears smaller than feared," they wrote. Read the original article on Business Insider Sign in to access your portfolio
